Shengtai Pharmaceutical Retains Grayling Global As Investor Relations Counsel
August 04 2008 - 8:30AM
PR Newswire (US)
WEIFANG, Shandong, China, Aug. 4 /Xinhua-PRNewswire-FirstCall/ --
Shengtai Pharmaceutical, Inc. (OTC:SGTI) (BULLETIN BOARD: SGTI)
("Shengtai Pharmaceutical" or "the Company"), a leading
manufacturer and distributor of high-quality, pharmaceutical grade
glucose products in China, today announced that it has retained
Grayling Global to lead a strategic communications program ("the IR
program") to shareholders, the investment community and financial
media. As the investor relations counsel for Shengtai
Pharmaceutical, Grayling Global will help raise the investment
community's awareness of the Company's performance through timely
corporate updates, direct communications with fund managers,
financial media placements and investor conference presentations.
"We are pleased to have a global IR network and its senior
counselors with long standing healthcare and industrial track
records to help us raise our financial profile and ensure the full
understanding of our business model and exciting growth prospects,"
said Mr. Qingtai Liu, Chief Executive Officer of Shengtai
Pharmaceutical. "We need to increase our visibility and expand our
relationships with U.S. investors. As we are becoming a bigger
company and planning to move onto main exchange, we believe
Grayling Global is best suited to guide this investor relations
process." Grayling Global, a subsidiary of Huntsworth PLC
(LSE:HNT), is headquartered in London, with offices in New York,
Brussels, Bangkok, Singapore, Madrid, Moscow, Tel Aviv, Hong Kong,
Istanbul, Los Angeles, Sacramento, Dublin, Edinburgh, Cardiff,
Bristol, and Birmingham. The firm has over 200 consultants,
focusing on first-class delivery in public affairs, public
relations, investor relations and events management. About Shengtai
Pharmaceutical, Inc. Shengtai Pharmaceutical, Inc. through its
wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New Jersey
corporation, and the Chinese operating company of Weifang Shengtai
Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of
pharmaceutical grade glucose used for medical purposes, and the
glucose and cornstarch products for the food and beverage industry
and for industrial production in China. For more information about
Shengtai Pharmaceutical, Inc., please visit
http://www.shengtaipharmaceutical.com/ . Safe Harbor Statement Safe
Harbor Statement under the Private Securities Litigation Reform Act
of 1995: Certain statements in this press release and oral
statements made by the Company constitute forward-looking
statements for purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. These statements
include, without limitation, statements regarding our ability to
prepare the company for growth, the Company's planned capacity
expansion in 2008 and predictions and guidance relating to the
Company's future financial performance. We have based these
forward-looking statements largely on our current expectations and
projections about future events and financial trends that we
believe may affect our financial condition, results of operations,
business strategy and financial needs but they involve risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements, which may include,
but are not limited to, such factors as unanticipated changes in
product demand especially in the pharmaceutical industry, pricing
and demand trends for the Company's products, changes to government
regulations, risk associated with operation of the Company's new
facilities, risk associated with large scale implementation of the
company's business plan, the ability to attract new customers,
ability to increase its product's applications, cost of raw
materials, downturns in the Chinese economy, and other information
detailed from time to time in the Company's filings and future
filings with the United States Securities and Exchange Commission.
Investors are urged to consider these factors carefully in
evaluating the forward-looking statements herein and are cautioned
not to place undue reliance on such forward-looking statements,
which are qualified in their entirety by this cautionary statement.
The forward-looking statements made herein speak only as of the
date of this press release and the Company undertakes no duty to
update any forward-looking statement to conform the statement to
actual results or changes in the company's expectations. For more
information, please contact: Shengtai Pharmaceutical, Inc. Ms.
Melody Shi Chief Financial Officer Tel: +1-949-468-7078 Email:
Grayling Global Eddie Cheung Investor Relations Tel:
+1-646-284-9414 Email: DATASOURCE: Shengtai Pharmaceutical, Inc.
CONTACT: Shengtai Pharmaceutical, Inc. - Ms. Melody Shi, Chief
Financial Officer, +1-949-468-7078, or ; Grayling Global - Eddie
Cheung of Investor Relations, +1-646-284-9414, or Web Site:
http://www.shengtaipharmaceutical.com/
Copyright